Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ZK 156979

Known as: ZK-156979, ZK156979 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
New signalling pathway involved in the anti-proliferative action of vitamin D3 and its analogues in human neuroblastoma cells. A role for ceramide kinase
1α,25-Dihydroxyvitamin D3 (1,25(OH)₂D₃), a crucial regulator of calcium/phosphorus homeostasis, has important physiological… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2010
2010
Down-regulation of adhesion molecules and matrix metalloproteinases by ZK 156979 in inflammatory bowel diseases.
Intracellular adhesion molecules and matrix metalloproteinases (MMPs) are up-regulated in intestinal mucosa of patients with… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2007
2007
22-ene-25-oxa-Vitamin D (ZK156979) führt über eine Beeinflussung der IL-23/IL-17/IL-6-Signalwege zu einer signifikanten Reduktion der experimentellen TNBS-Colitis der Maus
 
Highly Cited
2006
Highly Cited
2006
The New Low Calcemic Vitamin D Analog 22-Ene-25-Oxa-Vitamin D Prominently Ameliorates T Helper Cell Type 1-Mediated Colitis in Mice
In addition to its well defined role as a key regulator of calcium and bone metabolism, 1,25-dihydroxyvitamin D3 (calcitriol) has… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2005
2005
22‐ene‐25‐oxa‐vitamin D: a new vitamin D analogue with profound immunosuppressive capacities
Background  The biologic role of 1,25‐dihydroxyvitamin D3, such as anti‐inflammatory functions, reduction of cytokine production… Expand
2005
2005
22-Ene–25-Oxa-vitamin D (ZK156979): ein neues niedrig calcämisches immunsuppressives Vitamin D-Analogon – Untersuchungen am TNBS-Modell der Maus
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE